Evommune (EVMN) Asset Utilization Ratio (2025 - 2026)
Evommune (EVMN) reported Asset Utilization Ratio of 0.05 for Q1 2026, down 43.46% quarter-over-quarter from 0.08 in Q4 2025.
Evommune (EVMN) Asset Utilization Ratio (2025 - 2026) Analysis & Trends
Evommune (EVMN) has 2 years of Asset Utilization Ratio data on file, last reported at 0.05 in Q1 2026.
- Asset Utilization Ratio for Q1 2026 came in at 0.05, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 0.05 (changed N/A YoY), and the FY2025 annual result was 0.09, changed N/A from the prior year.
- Asset Utilization Ratio slipped to 0.05 in Q1 2026 per EVMN's latest filing, from 0.08 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 0.08 in Q4 2025 and troughed at 0.05 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 0.55 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.60 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 1,422.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 0.47 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Evommune | 695.29 Mn | 483.82 Mn | - | 0.05 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.05 |
| Dec 31, 2025 | 0.08 |